Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma [0.03%]
大B细胞淋巴瘤CAR-T细胞治疗的长期疗效和晚期毒性反应
Rafaella Litvin,Brian T Hill
Rafaella Litvin
Introduction: Chimeric antigen receptor (CAR) T-cell therapies have rapidly become an integral part of the treatment landscape for relapsed or refractory lymphomas. While early clinical trials demonstrated impressive resp...
A situational analysis of the adoption of oncology, inflammation, and supportive care biosimilars in the United States [0.03%]
美国肿瘤学、炎症和辅助治疗生物仿制药采用情况分析
Bhavesh Shah,Josephine Kim,Ann Wicker et al.
Bhavesh Shah et al.
Introduction: The rapid development and approval of biosimilars in the US offer a critical opportunity to improve the affordability and accessibility of biologic therapies. ...
Biological therapies at 25 years: from incremental advances to revolutionary transformations [0.03%]
生物治疗25年：从渐进式进展到革命性变革
Thomas A Ciulla
Thomas A Ciulla
The future of gene therapy for inborn errors of metabolism: insights into liver-targeted innovations [0.03%]
针对肝脏的基因治疗创新为先天性代谢错误的基因治疗带来未来展望及启示
Gloria Gonzalez-Aseguinolaza,Pasquale Piccolo
Gloria Gonzalez-Aseguinolaza
Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents [0.03%]
胃癌患者Claudin 18.2靶点新兴生物制剂疗法盘点
Kazumasa Yamamoto,Izuma Nakayama,Kohei Shitara
Kazumasa Yamamoto
Introduction: Zolbetuximab, the first monoclonal antibody targeting claudin 18.2 (CLDN18.2), is approved as first-line treatment for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction c...
Exploring the inherent susceptibility of cancer-associated fibroblasts to oncolytic virus infection [0.03%]
探究癌症相关成纤维细胞感染溶瘤病毒的内在敏感性
Nicole Dam,Gavriil Ioannidis,Lukas J A C Hawinkels et al.
Nicole Dam et al.
Introduction: Oncolytic virus (OV) therapy represents a promising approach currently undergoing (pre)-clinical testing for several cancers. Until recently, it was thought that the tropism of oncolytic viruses was restrict...
Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease [0.03%]
评估克唑替尼对轴性脊柱关节炎疗效的影响：对银屑病和炎症性肠病亚组疾病活动度、生活质量及生产率的影响
Nikolaos Kougkas,Elpida Skouvaklidou,Dimitrios Deligeorgakis et al.
Nikolaos Kougkas et al.
Background: Axial spondyloarthritis (axSpA) leads to significant impairments in quality of life (QoL) and work productivity. While infliximab is effective in treating axSpA, its impact in patients with concomitant extra-s...
Targeting two pathways at once: the emerging role of bispecific antibodies in NSCLC and SCLC [0.03%]
双重阻断：双特异抗体在NSCLC和SCLC中的新兴角色
Roupen Odabashian,Hirva Mamdani
Roupen Odabashian
Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats [0.03%]
仿生类似物作为抗病毒药物：在感染威胁中快速、低成本部署的科学和监管准备程度
Ahmad Z Al Meslamani,Anan S Jarab,Eman Merghani Ali Mohammed et al.
Ahmad Z Al Meslamani et al.
Introduction: Rapid and equitable access to antiviral biologics in outbreaks is constrained by bespoke manufacturing, lengthy trials, and uneven procurement. Biosimilar antivirals could change responsiveness from single-s...
Correction [0.03%]
改正措施
Published Erratum
Expert opinion on biological therapy. 2025 Dec 25:1. DOI:10.1080/14712598.2025.2610041 2025